Clinical Performance of the Implantable Cardioverter‐Defibrillator

M. MIROWSKI, PHILIP R. REID, MORTON M. MOWER, LEVI WATKINS, EDWARD V. PLATIA, LAWRENCE S.C. GRIFFITH, THOMAS GUARNIERI, ANDRA THOMAS, JUAN M. JUANTEGUY

Research output: Contribution to journalArticlepeer-review

Abstract

The automatic implantable cardioverter‐defibrillator has been implanted in 276 patients with ventricular tachyarrhythmias refractory to therapy with a follow‐up period up to 50 months (average 9.75 months). The functional performance of the device has so far been most encouraging. The risks and complications associated with its use are acceptable and quite similar to those observed in patients with implanted pacemakers. Acceleration of ventricular tachycardia to a faster rhythm or to ventricular fibrillation is dealt with successfully through recycling. Actuarial analysis indicates that the device has a significant impact on the survival rate of the implantees, reducing the one‐year mortality rate attributed to arrhythmias to only 2%.

Original languageEnglish (US)
Pages (from-to)1345-1350
Number of pages6
JournalPacing and Clinical Electrophysiology
Volume7
Issue number6
DOIs
StatePublished - Nov 1984

Keywords

  • implantable dafibrillator
  • sudden death
  • ventricular arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Clinical Performance of the Implantable Cardioverter‐Defibrillator'. Together they form a unique fingerprint.

Cite this